Group 1 - The core viewpoint is that China's biopharmaceutical sector is experiencing significant growth in research and development capabilities, with a notable increase in the number of new drug approvals [1] - In 2023, the National Medical Products Administration (NMPA) approved 87 drugs, including 5 domestically innovative drugs, indicating a strengthening of China's drug development landscape [1] - The number of external licensing transactions has increased from 15 in 2019 to 33 in 2023, reflecting growing international confidence in Chinese biotechnology products [1] Group 2 - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies listed on the STAR Market, tracking an index of 30 representative high-quality companies [1] - Since the "924 market" period, the STAR Market innovative drug index has outperformed the Hang Seng Hong Kong Stock Connect innovative drug index, with respective gains of 117.04% and 109.62% during the market rebound from September 24, 2024, to September 30, 2025 [1] - The STAR Market innovative drug index may provide better exposure to the resilience of the STAR Market when market risk appetite increases [1]
20cm速递|科创创新药ETF国泰（589720）回调近3%，中国研发能力不断增强，回调或可布局
Mei Ri Jing Ji Xin Wen·2025-11-04 04:57